LIEN:NASDAQChicago Atlantic BDC, Inc. Analysis
Data as of 2026-04-15 - not real-time
$9.44
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Chicago Atlantic BDC (LIEN) is trading at $9.44, well below its 20‑day ($9.54), 50‑day ($9.87) and 200‑day ($10.38) moving averages, indicating a short‑term bearish bias. The stock sits just above the calculated support of $9.16 and faces resistance near $10.20, while volume has been trending downwards. Valuation metrics are compelling – a trailing P/E of 6.4 versus an industry average of 17.5, a price‑to‑book of 0.71 and a DCF‑derived fair value of $28.75 suggest significant upside potential, estimated at roughly 16.5% by the model. However, the company carries a very high debt‑to‑equity ratio of 8.24, negative operating cash flow and a dividend payout ratio of 93%, raising concerns about the sustainability of its 14.4% yield.
The latest earnings release highlights robust credit performance: $31.7 million of new senior‑secured, floating‑rate loans originated, $11 million of repayments collected, and zero loans in non‑accrual status (industry average 3.3%). While revenue grew 12.5% year‑over‑year and margins remain strong (>55% operating, >60% net), the firm’s exposure to the cannabis sector adds a layer of regulatory risk. The market sentiment is extremely bullish (Fear‑Greed Index 88.6), but the combination of high leverage, dividend sustainability doubts, and sector‑specific regulatory uncertainty tempers enthusiasm.
The latest earnings release highlights robust credit performance: $31.7 million of new senior‑secured, floating‑rate loans originated, $11 million of repayments collected, and zero loans in non‑accrual status (industry average 3.3%). While revenue grew 12.5% year‑over‑year and margins remain strong (>55% operating, >60% net), the firm’s exposure to the cannabis sector adds a layer of regulatory risk. The market sentiment is extremely bullish (Fear‑Greed Index 88.6), but the combination of high leverage, dividend sustainability doubts, and sector‑specific regulatory uncertainty tempers enthusiasm.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Price below all key moving averages and decreasing volume
- High debt load and near‑full dividend payout ratio
- Proximity to support level with limited upside in the near term
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation discount (low P/E, P/B, DCF upside)
- Strong loan performance with zero non‑accruals and active new originations
- Target price consensus around $11 indicating ~16% upside
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Regulatory uncertainty in the cannabis financing space
- High leverage may constrain future cash generation
- Attractive dividend yield if sustainable, but dependent on cash flow trends
Key Metrics & Analysis
Financial Health
Revenue Growth12.50%
Profit Margin61.29%
P/E Ratio6.4
ROE11.01%
ROA6.20%
Debt/Equity8.24
P/B Ratio0.7
Op. Cash Flow$-20477732
Free Cash Flow$29.7M
Industry P/E17.5
Technical Analysis
TrendBearish
RSI43.1
Support$9.16
Resistance$10.20
MA 20$9.54
MA 50$9.87
MA 200$10.38
MACDBullish
VolumeDecreasing
Fear & Greed Index88.64
Valuation
Fair Value$28.75
Target Price$11.00
Upside/Downside16.53%
GradeUndervalued
TypeBlend
Dividend Yield14.41%
Risk Assessment
Beta0.17
Volatility20.83%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.